SG188543A1 - Use of myeloid cell biomarkers for the diagnosis of cancer - Google Patents
Use of myeloid cell biomarkers for the diagnosis of cancer Download PDFInfo
- Publication number
- SG188543A1 SG188543A1 SG2013018973A SG2013018973A SG188543A1 SG 188543 A1 SG188543 A1 SG 188543A1 SG 2013018973 A SG2013018973 A SG 2013018973A SG 2013018973 A SG2013018973 A SG 2013018973A SG 188543 A1 SG188543 A1 SG 188543A1
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- patient
- treatment
- mdsc
- treated
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 131
- 201000011510 cancer Diseases 0.000 title claims description 98
- 239000000090 biomarker Substances 0.000 title abstract description 13
- 210000000066 myeloid cell Anatomy 0.000 title abstract description 10
- 238000003745 diagnosis Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 67
- 238000011282 treatment Methods 0.000 claims abstract description 58
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract description 57
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 26
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 22
- 238000004393 prognosis Methods 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 11
- 238000012544 monitoring process Methods 0.000 claims abstract description 11
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 109
- 238000002203 pretreatment Methods 0.000 claims description 28
- 230000004083 survival effect Effects 0.000 claims description 24
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 23
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 23
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 23
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 21
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 19
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 19
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 16
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 15
- 229940022399 cancer vaccine Drugs 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 14
- 230000028993 immune response Effects 0.000 claims description 13
- 238000009169 immunotherapy Methods 0.000 claims description 13
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 239000013610 patient sample Substances 0.000 claims description 12
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 11
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 11
- 206010017758 gastric cancer Diseases 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 11
- 201000011549 stomach cancer Diseases 0.000 claims description 11
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 10
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 10
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 10
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229960003787 sorafenib Drugs 0.000 claims description 10
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 9
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 9
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 9
- 208000009956 adenocarcinoma Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 9
- 229960001796 sunitinib Drugs 0.000 claims description 9
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 8
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 8
- 238000000684 flow cytometry Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 230000001976 improved effect Effects 0.000 claims description 7
- 230000001394 metastastic effect Effects 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 102100035793 CD83 antigen Human genes 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 5
- 238000010186 staining Methods 0.000 claims description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 230000005751 tumor progression Effects 0.000 claims description 3
- 238000011394 anticancer treatment Methods 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 238000004163 cytometry Methods 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 7
- 238000003748 differential diagnosis Methods 0.000 abstract description 3
- 201000009030 Carcinoma Diseases 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 229940124672 IMA901 Drugs 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000007654 attenuated familial adenomatous polyposis Diseases 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 239000012931 lyophilized formulation Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- 229940124673 IMA910 Drugs 0.000 description 2
- 108010016032 IMA950 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 238000003657 Likelihood-ratio test Methods 0.000 description 2
- 102000017794 Perilipin-2 Human genes 0.000 description 2
- 108010067163 Perilipin-2 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000018757 Apolipoprotein L1 Human genes 0.000 description 1
- 108010052469 Apolipoprotein L1 Proteins 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 101001013520 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP7 Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101000736906 Homo sapiens Protein prune homolog 2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- -1 IL-1beta Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 241001647769 Mirza Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100036040 Protein prune homolog 2 Human genes 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478410P | 2010-09-21 | 2010-09-21 | |
| GBGB1015765.9A GB201015765D0 (en) | 2010-09-21 | 2010-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| PCT/EP2011/066397 WO2012038463A2 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG188543A1 true SG188543A1 (en) | 2013-04-30 |
Family
ID=43065538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013018973A SG188543A1 (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
| SG10201510470WA SG10201510470WA (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201510470WA SG10201510470WA (en) | 2010-09-21 | 2011-09-21 | Use of myeloid cell biomarkers for the diagnosis of cancer |
Country Status (10)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| WO2012149416A2 (en) * | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013169913A1 (en) | 2012-05-08 | 2013-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Predictors of patient response to interferon-a therapy |
| US20160030558A1 (en) * | 2013-03-13 | 2016-02-04 | Health Research, Inc. | Enhancement of vaccines |
| CN103743907B (zh) * | 2013-07-24 | 2015-04-15 | 北京大学人民医院 | 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法 |
| WO2015048748A1 (en) * | 2013-09-30 | 2015-04-02 | Board Of Regents, The University Of Texas System | Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use |
| CN103626846B (zh) * | 2013-11-08 | 2016-06-01 | 上海交通大学 | 与MDSCs特异性结合的配体多肽及药物输送系统 |
| EP3012271A1 (en) * | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| AU2016282986A1 (en) * | 2015-06-26 | 2018-02-01 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| JP2018527570A (ja) | 2015-09-02 | 2018-09-20 | シンダックス ファーマシューティカルズ，インク． | 併用療法のための患者の選択 |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| EP4438626A3 (en) | 2016-04-14 | 2024-12-04 | OSE Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| KR102639592B1 (ko) | 2016-12-08 | 2024-02-21 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN107102127B (zh) * | 2017-04-07 | 2019-08-06 | 东北师范大学 | 一种人体外周血中单核样髓源抑制细胞的检测方法 |
| AU2018269039B2 (en) | 2017-05-19 | 2025-05-15 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| WO2018221820A1 (ko) * | 2017-06-02 | 2018-12-06 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
| KR20200087143A (ko) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | 핫스팟을 이용한 신생항원 동정 |
| CN111511766B (zh) | 2017-10-13 | 2024-06-07 | Ose免疫疗法 | 修饰的抗SIRPa抗体及其应用 |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
| AU2019233577A1 (en) | 2018-03-13 | 2020-09-03 | Ose Immunotherapeutics | Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies |
| BR112020022542A2 (pt) | 2018-05-07 | 2021-02-02 | Syndax Pharmaceuticals, Inc. | seleção de pacientes para terapia combinada |
| CN110501483B (zh) * | 2019-07-25 | 2020-12-29 | 同济大学 | 一种中草药活性的检测方法 |
| TR202003833A1 (tr) | 2020-03-12 | 2021-09-21 | Hacettepe Ueniversitesi Rektoerluek | Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇ |
| AU2022284373A1 (en) | 2021-06-04 | 2024-01-04 | Boehringer Ingelheim International Gmbh | Anti-sirp-alpha antibodies |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
| CN117030580B (zh) * | 2023-09-15 | 2024-07-16 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | LDNs在坏死性小肠结肠炎诊断中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US20040136973A1 (en) * | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
| US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| GB0820698D0 (en) * | 2008-11-12 | 2008-12-17 | Ludwig Inst Cancer Res | Uses of immunomodulators |
-
2010
- 2010-09-21 GB GBGB1015765.9A patent/GB201015765D0/en not_active Ceased
-
2011
- 2011-09-21 WO PCT/EP2011/066397 patent/WO2012038463A2/en active Application Filing
- 2011-09-21 EP EP11758209.8A patent/EP2619585B1/en active Active
- 2011-09-21 KR KR1020137010009A patent/KR20130137635A/ko not_active Withdrawn
- 2011-09-21 JP JP2013528723A patent/JP5970459B2/ja not_active Expired - Fee Related
- 2011-09-21 EA EA201390413A patent/EA201390413A1/ru unknown
- 2011-09-21 CN CN201180045200.3A patent/CN103180739B/zh not_active Expired - Fee Related
- 2011-09-21 SG SG2013018973A patent/SG188543A1/en unknown
- 2011-09-21 SG SG10201510470WA patent/SG10201510470WA/en unknown
- 2011-09-21 CA CA2811070A patent/CA2811070A1/en not_active Abandoned
- 2011-09-21 US US13/239,011 patent/US9671404B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5970459B2 (ja) | 2016-08-17 |
| KR20130137635A (ko) | 2013-12-17 |
| EA201390413A1 (ru) | 2013-07-30 |
| WO2012038463A3 (en) | 2012-07-26 |
| SG10201510470WA (en) | 2016-01-28 |
| EP2619585B1 (en) | 2017-03-01 |
| US9671404B2 (en) | 2017-06-06 |
| GB201015765D0 (en) | 2010-10-27 |
| JP2013539857A (ja) | 2013-10-28 |
| US20120070461A1 (en) | 2012-03-22 |
| CA2811070A1 (en) | 2012-03-29 |
| WO2012038463A2 (en) | 2012-03-29 |
| CN103180739B (zh) | 2016-08-03 |
| CN103180739A (zh) | 2013-06-26 |
| EP2619585A2 (en) | 2013-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9671404B2 (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
| Eugène et al. | The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression | |
| Wu et al. | Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia | |
| US9389235B2 (en) | Methods of using biomarkers for predicting the outcome of an immunotherapy against cancer | |
| Kim et al. | Dynamic changes in circulating PD-1+ CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | |
| EP3022561B1 (en) | Method for the prognosis of survival time of a patient suffering from a solid cancer | |
| US20210017607A1 (en) | Methods of Predicting Responsiveness to Cancer Therapies | |
| Nakamura et al. | Immunologic parameters as significant prognostic factors in lung cancer | |
| Akazawa et al. | Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes | |
| Yu et al. | CCR9-CCL25 mediated plasmacytoid dendritic cell homing and contributed the immunosuppressive microenvironment in gastric cancer | |
| JP7216420B2 (ja) | がん治療効果の検査方法及び免疫応答誘導用組成物 | |
| Schmitt et al. | The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses | |
| Andersson et al. | Prognostic significance of specific anti‐WT 1 IgG antibody level in plasma in patients with ovarian carcinoma | |
| HK1183096A (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
| HK1183096B (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
| Copier et al. | Biomarkers for the development of cancer vaccines: current status | |
| Zhang et al. | BPIFB2 is highly expressed in “cold” lung adenocarcinoma and decreases T cell chemotaxis via activation of the STAT3 pathway | |
| Camcı et al. | Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer | |
| Li et al. | Longitudinal high-dimensional analysis identifies biomarkers of response to anti-PD-1 immunotherapy | |
| Jeon et al. | Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer | |
| Sesma et al. | Peripheral blood TCRβ repertoire, IL15, IL2 and soluble ligands for NKG2D activating receptor predict efficacy of ICI in lung cancer | |
| Kostine | Defining the immune microenvironment in sarcoma: could immunotherapy be part of the treatment strategy in sarcoma patients? | |
| Xie et al. | Diagnostic value of the circulating tumor cells and circulating tumor-derived endothelial cells detection for non-small cell lung cancer | |
| JP2024151758A (ja) | 肝臓癌を治療する方法、治療に対する応答を予測する方法、及び肝臓癌の治療中の有害作用を予測する方法 | |
| Tarhoni | Characterization of Biomarkers Associated with Response to Programmed Cell Death Protein-1/Programmed Cell Death Ligand-1 Inhibition in Patients with Advanced Stage Non-small Cell Lung Cancer |